Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Short-term Investments: 2017-2025

Historic Short-term Investments for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $593.0 million.

  • Arcus Biosciences' Short-term Investments fell 33.22% to $593.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $593.0 million, marking a year-over-year decrease of 33.22%. This contributed to the annual value of $828.0 million for FY2024, which is 31.01% up from last year.
  • Latest data reveals that Arcus Biosciences reported Short-term Investments of $593.0 million as of Q3 2025, which was down 10.56% from $663.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Short-term Investments high stood at $900.1 million for Q2 2022, and its period low was $345.2 million during Q3 2021.
  • Moreover, its 3-year median value for Short-term Investments was $716.0 million (2023), whereas its average is $733.0 million.
  • Data for Arcus Biosciences' Short-term Investments shows a peak YoY increase of 382.29% (in 2021) and a maximum YoY decrease of 38.42% (in 2021) over the last 5 years.
  • Over the past 5 years, Arcus Biosciences' Short-term Investments (Quarterly) stood at $351.0 million in 2021, then spiked by 128.77% to $803.0 million in 2022, then fell by 21.30% to $632.0 million in 2023, then surged by 31.01% to $828.0 million in 2024, then plummeted by 33.22% to $593.0 million in 2025.
  • Its Short-term Investments stands at $593.0 million for Q3 2025, versus $663.0 million for Q2 2025 and $805.0 million for Q1 2025.